Evaluation of inhaled dry powder tobramycin free base in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – Clinical and microbiological aspects of bronchiectasis and non-tuberculous mycobacterium (NTM) infections Year: 2016
Antimicrobial efficacy of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Efficacy and safety of ciprofloxacin dry powder for inhalation in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Advances in antibiotic therapy of non-cystic fibrosis bronchiectasis Year: 2011
Effect of azithromycin on FEV1 and exacerbation frequency in adult non-cystic fibrosis bronchiectasis Source: Eur Respir J 2007; 30: Suppl. 51, 528s Year: 2007
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis Source: Annual Congress 2007 - Infectious lung and pleural diseases Year: 2007
Effect of short-term inhalation of warm saline atomised gas on patients with non-cystic fibrosis bronchiectasis Source: ERJ Open Res, 6 (1) 00130-2019; 10.1183/23120541.00130-2019 Year: 2020
Aerozolized colistin therapy in non-cystic fibrosis patients with bronchiectasis Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Adherence with inhaled colistimethate sodium during a 6 month study in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013
Ataluren in nonsense mutation cystic fibrosis patients not receiving chronic inhaled tobramycin: Evaluation of exacerbations and lung function Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016
Control of the inhalation technique in cystic fibrosis patients Source: Eur Respir J 2006; 28: Suppl. 50, 262s Year: 2006
Demographics and characteristics of antibiotic use in non-cystic fibrosis bronchiectasis patients Source: International Congress 2016 – From pleura to bronchi: new insights Year: 2016
The effect of gender on sputum microbiological profile in non-cystic fibrosis bronchiectasis Source: International Congress 2017 – Bronchiectasis and NTM infections: epidemiology, phenotyping and therapeutic strategies Year: 2017
Impact of bronchiectasis and trapped air on quality of life and exacerbations in cystic fibrosis Source: Eur Respir J 2013; 42: 371-379 Year: 2013
Influence of severity on outcome in a phase II trial of ciprofloxacin DPI in patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2013 –Treating bronchiectasis in respiratory patients Year: 2013
Long-term administration of aerosolised tobramycin in patients with cystic fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 619s Year: 2005
Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis Source: Eur Respir J 2002; 20: 122-126 Year: 2002
Functional respiratory imaging assessment of the aerosol deposition of inhaled levofloxacin in cystic fibrosis lungs Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021
Assessing response to treatment of exacerbations of bronchiectasis in adults Source: Eur Respir J 2009; 33: 312-318 Year: 2009
Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection Source: International Congress 2014 – Cystic fibrosis: assessment and treatment Year: 2014
Survey of microbiology, pseudomonas eradication and antimicrobial prophylaxis in adult patients with non-cystic fibrosis bronchiectasis Source: Annual Congress 2011 - Pseudomonas aeruginosa infection and non-cystic fibrosis bronchiectasis Year: 2011